Date: 2017-03-27
Type of information: Private placement
Company: adaptimmune
Investors:
Amount: $61.8 million
Funding type: private placement
Planned used:
- Net proceeds to be used to advance Adaptimmune’s wholly-owned pipeline of SPEAR® T-cell candidates through clinical trials as well as for other general corporate purposes.
Others:
- • On March 27, 2017, Adaptimmune Therapeutics announced the closing of its previously announced underwritten public offering of its American Depositary Shares . Adaptimmune sold 15,700,223 ADSs at a price to the public of $4.20 per ADS, which included 1,400,223 ADSs sold pursuant to the exercise of the underwriters’ option to purchase up to 2,145,000 additional ADSs. The net proceeds to Adaptimmune from the offering are approximately $61.8 million, after deducting the underwriting discount and other offering expenses payable by the company.
- • On March 22, 2017, Adaptimmune Therapeutics announced the pricing of an underwritten public offering of 14,300,000 of its American Depositary Shares at a price to the public of $4.20 per ADS. In connection with the offering, Adaptimmune has granted the underwriters a 30-day option to purchase up to an additional 2,145,000 ADSs at the public offering price. The gross offering size for this offering is expected to be approximately $ 60.1 million, excluding any exercise of the underwriters' option to purchase additional ADSs. This offering is expected to close on or about March 27, 2017, subject to customary closing conditions.
- • On March 21, 2017, Adaptimmune Therapeutics announced that it intends to offer and sell American Depositary Shares in an underwritten public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Adaptimmune also expects to grant the underwriters a 30-day option to purchase additional ADSs at the public offering price. Citigroup, Cowen and Company and Leerink Partners are acting as joint book-running managers for the offering. A shelf registration statement on Form S-3 relating to the public offering of the ADSs described above was declared effective by the Securities and Exchange Commission on September 12, 2016.
Therapeutic area: Cancer - Oncology
Is general: Yes
